Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 823 posts found.

Novartis’ Afinitor gets EU approval to treat cancerous gastrointestinal or lung tumors

June 2, 2016
Research and Development, Sales and Marketing Afinitor, Cancer, European Commission, Novartis, regulation

Swiss drugmaker Novartis (VTX: NOVN) on Thursday said the European Commission has approved its Afinitor (everolimus) to treat cancerous gastrointestinal …

News
clinical_trial_4

Phase III trials to start in Novartis/Genmab multiple sclerosis collaboration

June 2, 2016
Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, ofatumumab, phase III

Genmab (NASDAQ: GEN) has announced that its collaboration partner, Novartis, is set to initiate Phase III trials for ofatumumab in …

News
novartis_outside_1

Novartis’ heart failure drug Entresto gets top US, EU recommendation

May 23, 2016
Research and Development, Sales and Marketing Ernesto, Novartis, heart failure, regulation

Swiss drugmaker Novartis (VTX: NOVN) said its heart failure drug Entresto (sacubitril/ valsartan) has secured top recommendations in the US …

News
novartis_side_building

Nice backs Novartis’ lung cancer drug

May 20, 2016
NHS, NICE, Novartis, ceritinib, lung cancer, recommendation, regulation

The National Institute for Health and Care Excellence (Nice) has recommended Novartis’ (VTX: NOVN) Ceritinib (zykadia) as a treatment for …

News
sample

Breast cancer trial stopped after meeting primary endpoint early

May 18, 2016
Research and Development LEE011, Novartis, breast cancer, progression free survival, ribociclib

A Phase III trial evaluating LEE011 (ribociclib), developed by Novartis, has been stopped early after a recommendation from an independent …

News

Novartis splits pharmaceuticals division into two business units

May 18, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Novartis, epstein, new division

Novartis has announced internal structural changes that it says will “focus” its pharmaceuticals division by creating two business units, Novartis …

News
174571_1

Novartis says trials show its COPD drug more effective versus GSK’s Seretide

May 16, 2016
Research and Development, Sales and Marketing GSK, Novartis, drug trial, research

Swiss drug firm Novartis (VTX: NOVN) said its asthma drug showed efficacy over GlaxoSmithKline’s (LSE: GSK) medicine in a comparison …

News
novartis_afinitor

Afinitor receives EU recommendation to treat rare lung cancer

April 29, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Afinitor, Novartis

Novartis has received a recommendation from the Committee for Medicinal Products for Human Use at the European Medicines Agency for …

News
novartis_horsham_site_closure

Novartis’ two cancer drugs get NICE backing as combination treatment for skin cancer

April 29, 2016
Medical Communications NICE, Novartis, combination therapy, regulation, skin cancer

The National Institute for Health and Care Excellence (NICE) on Friday backed a combination therapy for skin cancer comprising two …

News
entresto

NICE gives green light to Novartis’s heart drug Entresto

April 27, 2016
Research and Development, Sales and Marketing Entresto, NHS, NICE, Novartis, benefit, heart failure, patients

NICE has published final guidance recommending heart failure drug Entresto (sacubritil/valsartan). The drug, developed by Novartis, has performed well in …

News
novartis_outside_1

Novartis’ Ilaris gets US FDA breakthrough therapy designation to treat fever syndromes

April 27, 2016
Business Services, Research and Development Breakthrough Therapy Designation, Novartis, US FDA, periodic fever syndromes

Novartis (VTX: NOVN) on Wednesday said its drug to treat three rare types of periodic fever syndromes has been granted …

News
novartis_mit_us

Novartis exploring almost $14-billion stake sale in Roche – reports

April 26, 2016
Manufacturing and Production, Sales and Marketing Financial, Merger & Acquisition, Novartis, Roche, Stake sale

Swiss pharma firm Novartis (VTX: NOVN) maybe looking at options to sell its one-third stake in cancer drugmaker Roche’s (VTX: …

News
lab

Novartis muscular drug fails in Phase III trials

April 22, 2016
Medical Communications, Research and Development FDA, Novartis, bimagrumab, breakthrough, morphosys, muscular, phase III

A muscular drug developed by Novartis (NYSE: NVS), in partnership with MorphoSys (ETR: MOR), failed to meet its primary endpoint …

News
afinitor_combo-front

Novartis drug Afinitor significantly reduces seizures in TSC patients

April 21, 2016
Research and Development Afinitor, Novartis, Tuberous Sclerosis Complex, drug, seizure, seizures, tsc

Novartis (SIX: NOVN) has announced the results from a Phase III clinical trial which shows that Afinitor (everolimus) significantly reduced …

News
novartis_side_building

Novartis Q1 earnings drop as cancer drug sales falter

April 21, 2016
Business Services, Sales and Marketing Financial, Novartis, earnings, first quarter, results

Swiss drugmaker Novartis (SIX: NOVN) on Thursday reported a 13% drop in net income for the first quarter on the …

News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026